Latin America Insulin Market Analysis, Opportunities 2031

Latin America Insulin Market Analysis, Opportunities 2031

Segments - Latin America Insulin Market by Products (Premixed Analog, Premixed Insulin, Rapid Acting Analog, Intermediate Insulin, Short-acting Insulin, and Long-acting Analog), Sources (Human Recombinant Insulin and Analogs), Applications (Type I and Type II Diabetes), and Geography (Brazil, Argentina, Chile, Mexico, Colombia, Venezuela, and Peru) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-2541 | 4.4 Rating | 60 Reviews | 190 Pages | Format : PDF Excel PPT

Report Description


The Latin America insulin market size was valued at USD 1.53 Billion in 2022 and is anticipated to reach USD 3.19 Billion by 2031, expanding at a CAGR of  8.5% during the forecast period,2023 – 2031. The growth of the market is attributed to the rising prevalence of diabetes along with the increasing geriatric population.

Latin America Insulin Market Outlook

Insulin is a hormone secreted by pancreas, produced by a number of cells called as the islets of Langerhans. The function of this hormone is to enable the access the glucose into the cells and induce energy to help regulate blood glucose levels at proper levels. Insulin is induced in patients who suffers from type I and type II diabetes. Type I diabetes is also referred to as insulin-dependent diabetes. A human with this type is not able to produce insulin. Patients with type II diabetes also demands insulin where the body demands for more insulin compared to the insulin which is already present in the body.

The International Diabetes Federation reported that the worldwide prevalence of diabetes is expected to increase from 364 million in 2011 to 552 million by the year 2030 and this rapid growth in incidence is expected to have a positive impact on the market growth in the coming years. The introduction of guidelines in favor of insulin manufacturers by government encouraged various multinational companies to enter into the market.

  • Entry of new multinational players and increasing competitive scope in the market is expected to boost the growth of the market in the coming years.
  • Rising prevalence of lifestyle induced disorders such as obesity, unusual diet habits, and consumption of unhealthy food products is further estimated to drive the market growth.
  • R&D initiatives focusing at developing new products and presence of favorable government policies are the key factors that can fuel the market growth in the projected timeline.

Scope of Insulin Market Report

The report on the Latin America insulin market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Insulin Market - Latin America Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Products (Premixed Analog, Premixed Insulin, Rapid Acting Analog, Intermediate Insulin, Short-Acting Insulin, And Long-Acting Analog), Sources (Human Recombinant Insulin and Analogs), and Applications (Type I and Type II Diabetes)

Geographical Scope

Brazil, Argentina, Chile, Mexico, Colombia, Venezuela, and Peru

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Eli Lilly and Company; Novo Nordisk; Sanofi Aventis; Oramed Pharmaceuticals; Takeda Pharmaceuticals Company Ltd.; Nanjing Xinbai Pharmaceutical Company Ltd.; Merck & Co. Inc.; Boehringer Ingelheim; and Biocon Ltd.

Insulin Market Segment Insights

Rapid-acting analog segment is expected to grow at a rapid pace

Based on products, the market is divided into premixed analog, premixed insulin, rapid acting analog, intermediate insulin, short-acting insulin, and long-acting analog. The rapid acting analog segment is anticipated to account for a key share of the market owing to presence of large products in pipeline in various countries in the region. However, the short-acting insulin segment is anticipated to expand at a rapid pace during the forecast period due to its patent expiration.

Latin America Insulin Market Product Segmentation

The Analogs segment is projected to expand at a considerable CAGR

On the basis of sources, the Latin America insulin market is divided into human recombinant insulin and analogs. The analogs segment to hold a significant market share owing to increasing market penetration of various new products. On the other hand, the human recombinant insulin segment is estimated to grow at a rapid pace during the forecast period due to increasing adoption rate in emerging economies.

Type I segment is expected to expand at a robust growth rate

In terms of applications, the market is divided into type I and type II Diabetes. The type I segment to account for a key share of the market owing to increasing usage of insulin for type I. Conversely, the type II segment is anticipated to expand at a rapid pace during the forecast period due to new product launches and rising prevalence of this type in the region.

Latin America Insulin Market Application Segmentation

Brazil is anticipated to constitute a large market share

Based on geography, the market is classified as Brazil, Argentina, Chile, Mexico, Colombia, Venezuela, and Peru. Brazil to account for a large share of the market owing to the various relaxations provided by the Brazil government to make the medicines affordable to the citizens.

Segments

The global Latin America insulin market has been segmented on the basis of

Products

  • Premixed Analog
  • Premixed Insulin
  • Rapid Acting Analog
  • Intermediate Insulin
  • Short-Acting Insulin
  • Long-Acting Analog

Sources

  • Human Recombinant Insulin
  • Analogs

Applications

  • Type I Diabetes
  • Type II Diabetes

Geography

  • Brazil
  • Argentina
  • Chile
  • Mexico
  • Colombia
  • Venezuela
  • Peru

Key Players

Competitive Landscape

Key players competing in the Latin America insulin market are Eli Lilly and Company; Novo Nordisk; Sanofi Aventis; Oramed Pharmaceuticals; Takeda Pharmaceuticals Company Ltd.; Nanjing Xinbai Pharmaceutical Company Ltd.; Merck & Co. Inc.; Boehringer Ingelheim; Biocon Ltd.

  • In February 2021, Biocon entered the generic drugs market in Latin America.

Latin America Insulin Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Insulin Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Insulin Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Insulin Market - Supply Chain
  4.5. Global Insulin Market Forecast
     4.5.1. Insulin Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Insulin Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Insulin Market Absolute $ Opportunity
5. Global Insulin Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Insulin Market Size and Volume Forecast by Applications
     5.3.1. Type I Diabetes Type II Diabetes
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Insulin Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Insulin Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Insulin Demand Share Forecast, 2019-2026
7. North America Insulin Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Insulin Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Insulin Market Size and Volume Forecast by Applications
     7.4.1. Type I Diabetes Type II Diabetes
  7.5. Basis Point Share (BPS) Analysis by Applications
  7.6. Y-o-Y Growth Projections by Applications
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Insulin Demand Share Forecast, 2019-2026
8. Latin America Insulin Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Insulin Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Insulin Market Size and Volume Forecast by Applications
     8.4.1. Type I Diabetes Type II Diabetes
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Insulin Demand Share Forecast, 2019-2026
9. Europe Insulin Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Insulin Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Insulin Market Size and Volume Forecast by Applications
     9.4.1. Type I Diabetes Type II Diabetes
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Insulin Demand Share Forecast, 2019-2026
10. Asia Pacific Insulin Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Insulin Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Insulin Market Size and Volume Forecast by Applications
     10.4.1. Type I Diabetes Type II Diabetes
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Insulin Demand Share Forecast, 2019-2026
11. Middle East & Africa Insulin Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Insulin Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Insulin Market Size and Volume Forecast by Applications
     11.4.1. Type I Diabetes Type II Diabetes
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Insulin Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Insulin Market: Market Share Analysis
  12.2. Insulin Distributors and Customers
  12.3. Insulin Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Eli Lilly and Company Novo Nordisk Sanofi Aventis Oramed Pharmaceuticals Takeda Pharmaceuticals Company Ltd. Nanjing Xinbai Pharmaceutical Company Ltd.  

Methodology

Our Clients

sinopec
Nestle SA
Pfizer
Deloitte
Siemens Healthcare
FedEx Logistics
General Mills
General Electric